Tevogen Bio (NASDAQ:TVGN – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($1.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $0.39, FiscalAI reports.
Tevogen Bio Stock Performance
NASDAQ:TVGN traded down $1.47 during midday trading on Friday, hitting $7.95. 20,555 shares of the company traded hands, compared to its average volume of 27,610. The firm’s fifty day moving average is $6.33 and its 200-day moving average is $14.49. Tevogen Bio has a 12-month low of $4.14 and a 12-month high of $75.50.
Analyst Ratings Changes
Several analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a report on Monday, April 20th. D. Boral Capital cut Tevogen Bio from a “buy” rating to a “hold” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen cut Tevogen Bio to a “strong sell” rating in a report on Saturday, March 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $100.00.
Institutional Trading of Tevogen Bio
Several hedge funds and other institutional investors have recently bought and sold shares of TVGN. Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after buying an additional 33,000 shares during the period. Goldman Sachs Group Inc. raised its holdings in Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after buying an additional 152,572 shares during the period. Finally, Deutsche Bank AG raised its holdings in Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares during the period.
Tevogen Bio Company Profile
Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).
In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.
Read More
- Five stocks we like better than Tevogen Bio
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
